Mediwound (MDWD) Given a $10.00 Price Target at Oppenheimer
Oppenheimer set a $10.00 price objective on Mediwound (NASDAQ:MDWD) in a research report sent to investors on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
MDWD has been the topic of a number of other research reports. Jefferies Group set a $10.00 target price on Mediwound and gave the company a buy rating in a research report on Friday, August 25th. SunTrust Banks set a $9.00 target price on Mediwound and gave the company a buy rating in a research report on Thursday, November 16th. Zacks Investment Research lowered Mediwound from a buy rating to a hold rating in a research report on Tuesday, November 21st. ValuEngine raised Mediwound from a strong sell rating to a sell rating in a research report on Saturday, November 25th. Finally, Cowen started coverage on Mediwound in a research report on Thursday, September 28th. They issued an outperform rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $9.13.
Shares of Mediwound (NASDAQ:MDWD) opened at $4.70 on Friday. Mediwound has a 1 year low of $4.15 and a 1 year high of $8.25.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related stocks with our FREE daily email newsletter.